Asthma: the role of fluticasone propionate.
This report reviews the evidence for the role of fluticasone propionate in the management of asthma, based on efficacy and safety trial data in over 4000 adults and more than 1600 children suffering from asthma of varying severity. Overall, fluticasone propionate at half the daily dose is at least as effective as budesonide and as effective as beclomethasone dipropionate across a range of doses.
D000293:Adolescent; D000328:Adult; D000730:Androstadienes / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000191:economics; D015415:Biomarkers / Q000097:blood; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D004305:Dose-Response Relationship, Drug; D005260:Female; D000068298:Fluticasone; D006128:Growth / Q000187:drug effects; D006801:Humans; D008297:Male
D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D015415:Biomarkers; D000068298:Fluticasone